Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 North America Benign Prostatic Hyperplasia Therapeutics Market, by Therapy
1.4.2 North America Benign Prostatic Hyperplasia Therapeutics Market, by Therapeutics Class
1.4.3 North America Benign Prostatic Hyperplasia Therapeutics Market, by Country
1.5 Methodology for the research
Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.1.1 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints
Chapter 3. North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
3.1 North America Mono Drug Therapy Market by Country
3.2 North America Combination Drug Therapy Market by Country
Chapter 4. North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
4.1 North America Alpha Blockers Market by Country
4.2 North America 5- alpha Reductase Inhibitors Market by Country
4.3 North America Phosphodiesterase-5 Inhibitors Market by Country
4.4 North America Others Market by Country
Chapter 5. North America Benign Prostatic Hyperplasia Therapeutics Market by Country
5.1 US Benign Prostatic Hyperplasia Therapeutics Market
5.1.1 US Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.1.2 US Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.2 Canada Benign Prostatic Hyperplasia Therapeutics Market
5.2.1 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.3 Mexico Benign Prostatic Hyperplasia Therapeutics Market
5.3.1 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.3.2 Mexico Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
5.4 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market
5.4.1 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapy
5.4.2 Rest of North America Benign Prostatic Hyperplasia Therapeutics Market by Therapeutics Class
Chapter 6. Company Profiles
6.1 GlaxoSmithKline PLC (GSK)
6.1.1 Company Overview
6.1.2 Financial Analysis
6.1.3 Segmental and Regional Analysis
6.1.4 Research & Development Expense
6.2 Astellas Pharma, Inc.
6.2.1 Company Overview
6.2.2 Financial Analysis
6.2.3 Regional Analysis
6.2.4 Research & Development Expense
6.3 Eli Lilly and Company
6.3.1 Company Overview
6.3.2 Financial Analysis
6.3.3 Regional Analysis
6.3.4 Research & Development Expense
6.4 Allergan PLC (AbbVie)
6.4.1 Company Overview
6.4.2 Financial Analysis
6.4.3 Regional Analysis
6.4.4 Research & Development Expense
6.5 Merck Group (Merck Sharp & Dohme Corp.)
6.5.1 Company Overview
6.5.2 Financial Analysis
6.5.3 Segmental and Regional Analysis
6.5.4 Research & Development Expense
6.6 Boehringer Ingelheim International Gmbh
6.6.1 Company Overview
6.6.2 Financial Analysis
6.6.3 Regional & Segmental Analysis
6.6.4 Research & Development Expenses
6.7 Teva Pharmaceutical Industries Ltd.
6.7.1 Company Overview
6.7.2 Financial Analysis
6.7.3 Regional Analysis
6.7.4 Research & Development Expenses
6.8 Sanofi S.A.
6.8.1 Company Overview
6.8.2 Financial Analysis
6.8.3 Segmental and Regional Analysis
6.8.4 Research & Development Expense
6.9 Pfizer, Inc.
6.9.1 Company Overview
6.9.2 Financial Analysis
6.9.3 Regional Analysis
6.9.4 Research & Development Expense
6.10. Abbott Laboratories
6.10.1 Company Overview
6.10.2 Financial Analysis
6.10.3 Segmental and Regional Analysis
6.10.4 Research & Development Expense
Unique Offerings 
